The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73605791" target="_blank" >RIV/61989592:15110/20:73605791 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/20:00116176 RIV/00216208:11130/20:10412532 RIV/65269705:_____/20:00072853 RIV/00064211:_____/20:W0000021 a 6 dalších

Výsledek na webu

<a href="https://aricjournal.biomedcentral.com/articles/10.1186/s13756-020-00765-y#citeas" target="_blank" >https://aricjournal.biomedcentral.com/articles/10.1186/s13756-020-00765-y#citeas</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s13756-020-00765-y" target="_blank" >10.1186/s13756-020-00765-y</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients

Popis výsledku v původním jazyce

Clostridium difficile, recently reclassified as Clostridioides difficile [1], is a leading pathogen of gastrointestinal infections in hospitalised patients [2]. Between 2005 and 2013, several European multicentre studies aimed at mapping C. difficile epidemiology in Europe and an increase of CDI incidence density was found to be concomitant with changes in prevailing ribotypes; however, the design of the studies varied [3]. To standardize CDI epidemiology data collection, the European centre for disease prevention and control (ECDC) released a surveillance protocol with three options of CDI surveillance intensity (“minimal, light and enhanced”). The “minimal option” collects hospital-level CDI data, the “light version” collects also CDI case-based data, including data on mortality. The “enhanced” option collects hospital data, CDI case based data and microbiological data. Microbiological data includes results on C. difficile isolates ribotyping, the presence of toxins A/B or toxin genes and antimicrobial susceptibility testing to metronidazole, vancomycin and moxifloxacin [3]. While metronidazole and vancomycin are recommended as CDI treatment drugs [4], a reduced susceptibility to moxifloxacin a fluoroquinolone class of drug, is suggested as an epidemiological marker for certain C. difficile ribotypes spread in healthcare settings [5].

Název v anglickém jazyce

The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients

Popis výsledku anglicky

Clostridium difficile, recently reclassified as Clostridioides difficile [1], is a leading pathogen of gastrointestinal infections in hospitalised patients [2]. Between 2005 and 2013, several European multicentre studies aimed at mapping C. difficile epidemiology in Europe and an increase of CDI incidence density was found to be concomitant with changes in prevailing ribotypes; however, the design of the studies varied [3]. To standardize CDI epidemiology data collection, the European centre for disease prevention and control (ECDC) released a surveillance protocol with three options of CDI surveillance intensity (“minimal, light and enhanced”). The “minimal option” collects hospital-level CDI data, the “light version” collects also CDI case-based data, including data on mortality. The “enhanced” option collects hospital data, CDI case based data and microbiological data. Microbiological data includes results on C. difficile isolates ribotyping, the presence of toxins A/B or toxin genes and antimicrobial susceptibility testing to metronidazole, vancomycin and moxifloxacin [3]. While metronidazole and vancomycin are recommended as CDI treatment drugs [4], a reduced susceptibility to moxifloxacin a fluoroquinolone class of drug, is suggested as an epidemiological marker for certain C. difficile ribotypes spread in healthcare settings [5].

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10606 - Microbiology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Antimicrobial Resistance and Infection Control

ISSN

2047-2994

e-ISSN

—

Svazek periodika

9

Číslo periodika v rámci svazku

98

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

"'98(1)'"-"'98(7)'"

Kód UT WoS článku

000552013900002

EID výsledku v databázi Scopus

2-s2.0-85087419563